Innovaspain.com has dedicated an article to the research undertaken by Iproteos, a company specialized in the discovery of drugs for diseases of the nervous system. This spin-off company of IRB Barcelona has demonstrated the effectiveness of a novel compound, IPR-19, to reverse the cognitive deficit associated with schizophrenia in mouse models. At present, this peptide is in the preclinical phase.
Link to Innovaspain.com
For the scientific community, the protein POP (prolyl oligopeptidase) is an attractive therapeutic target for the treatment of cognitive and neurodegenerative disorders.
Scientists at IRB Barcelona have developed the first POP inhibitors that are irreversible, selective and brain-permeable.
El Economista, ABC and Diario Médico, among other media, have published an article about the event organised by IRB Barcelona and ESADE to call on the business and innovation sectors to manifest commitment to the fight against cancer metastasis.
Link to El Economista
Link to ABC
High-ranking figures from the business and innovation sectors attended an event organised by IRB Barcelona and ESADE with the aim to highlight the importance of uniting all sectors of society against metastasis.
